BioNTech (NASDAQ:BNTX) Given New $171.44 Price Target at Canaccord Genuity Group

BioNTech (NASDAQ:BNTX) had its price objective boosted by Canaccord Genuity Group from $171.00 to $171.44 in a research note issued to investors on Wednesday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the company. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft increased their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, September 19th. Bank of America boosted their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and increased their price objective for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Stock Up 1.8 %

Shares of NASDAQ:BNTX opened at $120.72 on Wednesday. The firm has a 50 day simple moving average of $113.42 and a 200 day simple moving average of $98.19. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market cap of $28.94 billion, a PE ratio of -57.48 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same quarter in the prior year, the company earned $0.73 earnings per share. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, research analysts expect that BioNTech will post -3.68 earnings per share for the current year.

Institutional Trading of BioNTech

Several large investors have recently modified their holdings of BNTX. Candriam S.C.A. lifted its position in BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in BioNTech by 63.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock valued at $2,249,000 after purchasing an additional 7,340 shares during the period. Discovery Capital Management LLC CT acquired a new stake in BioNTech in the 2nd quarter valued at approximately $2,467,000. Finally, Deerfield Management Company L.P. Series C increased its position in BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after buying an additional 24,426 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.